Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Interest & Investment Income (2016 - 2023)

Gyre Therapeutics (GYRE) has disclosed Interest & Investment Income for 14 consecutive years, with $47000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Interest & Investment Income fell 83.39% to $47000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $384000.0, a 19.33% decrease, with the full-year FY2022 number at $717000.0, up 1938.46% from a year prior.
  • Interest & Investment Income was $47000.0 for Q3 2023 at Gyre Therapeutics, down from $73000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.0 million in Q1 2020 to a low of -$74000.0 in Q4 2021.
  • A 5-year average of $245611.1 and a median of $107500.0 in 2020 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 112.48% in 2021, then surged 870.59% in 2022.
  • Gyre Therapeutics' Interest & Investment Income stood at $489000.0 in 2019, then increased by 21.27% to $593000.0 in 2020, then tumbled by 112.48% to -$74000.0 in 2021, then surged by 327.03% to $168000.0 in 2022, then crashed by 72.02% to $47000.0 in 2023.
  • Per Business Quant, the three most recent readings for GYRE's Interest & Investment Income are $47000.0 (Q3 2023), $73000.0 (Q2 2023), and $96000.0 (Q1 2023).